Prognostic Value of Stem Cell Related Markers
Withdrawn
- Conditions
- Breast Cancer
- Registration Number
- NCT01265225
- Lead Sponsor
- The Baruch Padeh Medical Center, Poriya
- Brief Summary
The goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-II breast cancer following surgery to remove the tumor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Ductal Carcinoma in Situ
- DCIS + Microinvasion stages 1 or 11 without positive lymph nodes
Exclusion Criteria
- tumor specimen with higher than grade II
- BRACA 1 or BRACA 2 mutation
- Neoadjuvant chemotherapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the prognostic significance of CD24, CD44, CD326, and EPCR in early-stage breast cancer recurrence prediction?
How do stem cell markers like CD44 and CD24 correlate with breast cancer metastasis and patient outcomes in stages 0-II?
Are there comparative studies evaluating CD24/CD44-based biomarkers against traditional methods for predicting breast cancer recurrence?
What molecular mechanisms link epithelial cell adhesion molecule (EPCAM/CD326) and endothelial protein C receptor (EPCR) to breast cancer stem cell behavior?
What adverse events are associated with CD24/CD44-targeted therapies in breast cancer and how are they managed?
Trial Locations
- Locations (1)
Baruch PMC
🇮🇱Poriya, Lower galilee, Israel
Baruch PMC🇮🇱Poriya, Lower galilee, Israel